2 2 Cystemic Solutions Limited 12337276 false 2023-12-01 2024-11-30 2024-11-30 The principal activity of the company is Cyber Security. Digita Accounts Production Advanced 6.30.9574.0 true 12337276 2023-12-01 2024-11-30 12337276 2024-11-30 12337276 bus:OrdinaryShareClass1 2024-11-30 12337276 core:CurrentFinancialInstruments core:WithinOneYear 2024-11-30 12337276 core:OfficeEquipment 2024-11-30 12337276 bus:SmallEntities 2023-12-01 2024-11-30 12337276 bus:AuditExemptWithAccountantsReport 2023-12-01 2024-11-30 12337276 bus:FilletedAccounts 2023-12-01 2024-11-30 12337276 bus:SmallCompaniesRegimeForAccounts 2023-12-01 2024-11-30 12337276 bus:RegisteredOffice 2023-12-01 2024-11-30 12337276 bus:Director1 2023-12-01 2024-11-30 12337276 bus:Director2 2023-12-01 2024-11-30 12337276 bus:OrdinaryShareClass1 2023-12-01 2024-11-30 12337276 bus:PrivateLimitedCompanyLtd 2023-12-01 2024-11-30 12337276 bus:Agent1 2023-12-01 2024-11-30 12337276 core:OfficeEquipment 2023-12-01 2024-11-30 12337276 countries:AllCountries 2023-12-01 2024-11-30 12337276 2023-11-30 12337276 core:OfficeEquipment 2023-11-30 12337276 2022-12-01 2023-11-30 12337276 2023-11-30 12337276 bus:OrdinaryShareClass1 2023-11-30 12337276 core:CurrentFinancialInstruments core:WithinOneYear 2023-11-30 12337276 core:OfficeEquipment 2023-11-30 xbrli:pure iso4217:GBP xbrli:shares

Registration number: 12337276

Cystemic Solutions Limited

Unaudited Filleted Financial Statements

for the Year Ended 30 November 2024

 

Cystemic Solutions Limited

Contents

Company Information

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

3 to 5

 

Cystemic Solutions Limited

Company Information

Directors

Mr Nigel Harrison

Karen Hewitt

Registered office

The Shop
Stainton House
Headley Road
Hindhead
Surrey
GU26 6LB

Accountants

Accounts Digital Limited
Chartered Certified AccountantsThe Shop
Stainton House
Headley Road
Hindhead
Surrey
GU26 6LB

 

Cystemic Solutions Limited

(Registration number: 12337276)
Balance Sheet as at 30 November 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

4

198

728

Current assets

 

Cash at bank and in hand

 

4,685

6,333

Creditors: Amounts falling due within one year

5

(4,041)

(4,064)

Net current assets

 

644

2,269

Net assets

 

842

2,997

Capital and reserves

 

Called up share capital

6

2

2

Retained earnings

840

2,995

Shareholders' funds

 

842

2,997

For the financial year ending 30 November 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 13 April 2025 and signed on its behalf by:
 

Mr Nigel Harrison
Director

 

Cystemic Solutions Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 November 2024

1

General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:
The Shop
Stainton House
Headley Road
Hindhead
Surrey
GU26 6LB
England

These financial statements were authorised for issue by the Board on 13 April 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office equipment

25.0% Straight Line

 

Cystemic Solutions Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 November 2024

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2023 - 2).

 

Cystemic Solutions Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 November 2024

4

Tangible assets

Office equipment
£

Total
£

Cost or valuation

At 1 December 2023

2,670

2,670

At 30 November 2024

2,670

2,670

Depreciation

At 1 December 2023

1,942

1,942

Charge for the year

530

530

At 30 November 2024

2,472

2,472

Carrying amount

At 30 November 2024

198

198

At 30 November 2023

728

728

5

Creditors

Creditors: amounts falling due within one year

2024
£

2023
£

Due within one year

Trade creditors

14

68

Taxation and social security

1,762

1,271

Accruals and deferred income

1,265

725

Other creditors

1,000

2,000

4,041

4,064

6

Share capital

Allotted, called up and fully paid shares

2024

2023

No.

£

No.

£

Ordinary Shares of £1 each

2

2

2

2